Literature DB >> 29396136

Renal replacement therapy in the neonatal intensive care unit.

Tze Yee Diane Mok1, Min-Hua Tseng2, Ming-Chou Chiang1, Ju-Li Lin1, Shih Ming Chu1, Jen-Fu Hsu1, Reyin Lien3.   

Abstract

BACKGROUND: Renal replacement therapy (RRT) is becoming increasingly necessary for supporting critically ill neonates. Few studies have reported the use of RRT in the neonatal intensive care unit (NICU). Therefore, we performed a retrospective study to describe the use of RRT in our NICU and its associated efficacy, complications, and outcomes.
METHODS: We identified patients requiring RRT between January 2009 and January 2017. Demographic data, mode of RRT, and associated factors were recorded. Efficacy was calculated as the percentage reduction in the blood urea nitrogen (BUN) or toxic metabolite level after 24 h of RRT. Complications including hypotension, electrolyte disturbance, and technical and catheter-related complications were documented. Measures of clinical outcome included in-hospital survival, presence of neurological sequelae, and chronic kidney disease. The chi-square test and Mann-Whitney U test were used for categorical and continuous variables, respectively.
RESULTS: We included 17 neonates in our study. The median gestational age at birth was 37 weeks (32-39 weeks), and the median birth weight was 2.7 kg (1.5-3.6 kg). Twelve neonates, including three with inborn errors of metabolism (IEM), received continuous RRT (CRRT), and five neonates underwent peritoneal dialysis (PD). The percentage reduction in ammonia in neonates with IEM who received CRRT was 87.2% at 24 h. The percentage reductions in BUN in the non-IEM neonates in the CRRT and PD groups were 33.7% and 23.7% at 24 h, respectively. The main complication was electrolyte disturbance including hypokalemia, hypocalcemia, and hypophosphatemia. All neonates with IEM survived, whereas the mortality rates for the non-IEM neonates in the CRRT and PD groups were 78% and 80%, respectively.
CONCLUSION: Our study findings reveal RRT to be feasible, even in preterm neonates with low birth weight. CRRT had a higher efficacy level, particularly in neonates with IEM, and the complications encountered were transient and correctable.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  acute kidney injury; continuous renal replacement therapy; inborn errors of metabolism; neonatal intensive care unit; peritoneal dialysis

Mesh:

Year:  2017        PMID: 29396136     DOI: 10.1016/j.pedneo.2017.11.015

Source DB:  PubMed          Journal:  Pediatr Neonatol        ISSN: 1875-9572            Impact factor:   2.083


  5 in total

1.  Mortality Risk Factors among Infants Receiving Dialysis in the Neonatal Intensive Care Unit.

Authors:  Keia R Sanderson; Bradley Warady; William Carey; Veeral Tolia; Marcella H Boynton; Daniel K Benjamin; Wesley Jackson; Matthew Laughon; Reese H Clark; Rachel G Greenberg
Journal:  J Pediatr       Date:  2021-11-16       Impact factor: 4.406

2.  Acute peritoneal dialysis is an efficient and reliable alternative therapy in preterm neonates with acute kidney injury.

Authors:  Yan Xing; Kai Sheng; Hui Liu; Song Wu; Hongling Wei; Rui Li; Jing Wang; Zailing Li; Xiaomei Tong
Journal:  Transl Pediatr       Date:  2021-04

3.  Continuous renal replacement therapy rescued life-threatening capillary leak syndrome in an extremely-low-birth-weight premature: a case report.

Authors:  Li-Fen Yang; Jia-Chang Ding; Ling-Ping Zhu; Li-Xia Li; Meng-Qi Duan; Zhuang-Gui Chen; Xin-Yi Tang; Ya-Ting Li
Journal:  Ital J Pediatr       Date:  2021-05-26       Impact factor: 2.638

4.  Clinical effect and safety of continuous renal replacement therapy in the treatment of neonatal sepsis-related acute kidney injury.

Authors:  Cheng Cai; Gang Qiu; Wenchao Hong; Yunlin Shen; Xiaohui Gong
Journal:  BMC Nephrol       Date:  2020-07-18       Impact factor: 2.388

5.  Challenges of acute peritoneal dialysis in extremely-low-birth-weight infants: a retrospective cohort study.

Authors:  Jihyun Noh; Chae Young Kim; Euiseok Jung; Joo Hoon Lee; Young-Seo Park; Byong Sop Lee; Ellen Ai-Rhan Kim; Ki-Soo Kim
Journal:  BMC Nephrol       Date:  2020-10-19       Impact factor: 2.388

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.